Search

Search Constraints

You searched for: Author/Creator Lawrence, Theodore

Search Results

1. Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: a propensity-matched national cancer database (ncdb) analysis. (2019)

2. CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES. (5th November 2018)

3. CTNI-15. PHASE 0/I TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH RADIATION TO OVERCOME GLIOBLASTOMA TREATMENT RESISTANCE BY TARGETING DE-NOVO PURINE METABOLISM: INTERIM REPORT. (12th November 2021)

4. CTNI-35. PHASE 0/1 TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH CHEMORADIATION TO OVERCOME TREATMENT RESISTANCE IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA BY TARGETING PURINE METABOLISM. (14th November 2022)

5. DDRE-19. PHASE 0/I TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH RADIATION TO OVERCOME GLIOBLASTOMA TREATMENT RESISTANCE BY TARGETING DE-NOVO PURINE METABOLISM. (25th March 2021)

6. DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE. (25th March 2021)

7. DDRE-28. MECHANISTIC AND THERAPEUTIC LINKS BETWEEN PURINE BIOSYNTHESIS AND DNA DAMAGE IN GLIOBLASTOMA. (25th March 2021)

8. EXTH-15. TARGETING ANDROGEN SIGNALING IN GLIOBLASTOMA (GBM) USING SEVITERONEL (SEVI), A CYP17 LYASE AND ANDROGEN RECEPTOR (AR) INHIBITOR, ALONE AND IN COMBINATION WITH RADIATION (RT). (5th November 2018)

9. First in Human Phase I Trial of Dual Vector (HSV1-TK, Flt3L) Immunotherapy For The Treatment of Newly Diagnosed High-Grade Glioma: Initial Results. (1st September 2019)

10. First in Human Phase I Trial of Dual Vector (HSV1‐TK, Flt3L) Immunotherapy For The Treatment of Newly Diagnosed High‐Grade Glioma: Initial Results. (September 2019)